F11 and deep vein thrombosis: Based on all previously mentioned phase 2 trials in the postsurgical VTE setting, human genetic deficiency data, and preclinical thrombosis models, we believe that >80% inhibition of FXI antigen/activity, the latter measured in a clot-based FXI assay, will result in clinically meaningful efficacy in humans.